May 24th, 2019

Allgenesis In The News: AG-86893, “The new drops that could help save eyesight and avoid the need for surgery”

In an effort to ramp up recruitment for our on-going Phase 2a study in Australia, Dr. Minas Coroneo, our KOL and one of the participating investigators, was interviewed by 9 News Australia in Sydney, discussing the potential benefits of AG-86893 in the treatment of Pterygium. For the video and online article, please click on the links below.

News Article: https://www.9news.com.au/national/news-health-eyedrops-tested-surfers-eye-avoid-surgery/6fa0f07f-4e12-4f49-8944-488e9c549277

About Allgenesis

Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases, and AG-86893 for pterygium.

About AG-86893

AG-86893 is a topical ocular eye drop reformulation of a marketed oral drug, a multi-tyrosine kinase inhibitor targeting receptors of growth factors such as VEGF, PDGF and FGF. AG-86893 is being developed for the treatment of pterygium, following a 505(B)(2) pathway. Currently, there is no approved treatment for pterygium other than surgery. A clinical Phase 2a trial (SURPH trial) for AG-86893 is being conducted for pterygium patients in Australia with FPE in 4Q2018.